ANTIMICROBIAL AND ANTIVIRAL AGENTS WITH POTENTIAL THERAPEUTIC USE FOR COVID-19
Abstract
The disease caused by the new SARS-CoV-2 coronavirus, called COVID-19, has already infected more than 6.5 million people worldwide. To date, there is no proven eff ective treatment against the virus, but some drugs already used in other diseases have shown eff ectiveness in vitro or even in humans, such as some antimicrobial agents. The objective of this bibliographic research was to provide an overview of the published evidence, up to the research date, about experimental studies and clinical trials that used antimicrobial drugs as a treatment proposal for the disease by the new coronavirus. 75 articles from journals indexed in the MEDLINE database were included. The results showed that the drugs Lopinavir/Ritonavir, chloroquine and hydroxychloroquine demonstrated to act in the clinical improvement of patients diagnosed with COVID-19. However, more evidence is needed to confi rm the data currently available.
Keywords
Full Text:
PDF (Português (Brasil))DOI: http://dx.doi.org/10.14450/2318-9312.v32.e2.a2020.pp109-119
Refbacks
- There are currently no refbacks.
Copyright (c) 2020 Hellen Cryslen Bernardo Bezerra, Daniel Parente Xavier, TATIANA PASCHOALETTE RODRIGUES BACHUR, Gislei Frota Aragão
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Infarma - Ciências Farmacêuticas
ISSN - 2318-9312 (Versão eletrônica)
ISSN - 0104-0219 (Versão impressa)
Conselho Federal de Farmácia - CFF
SHIS QI 15 Lote "L" - Lago Sul - Brasília - DF
CEP: 71635-615 - Fone: (61)3878-8751
e-mail:infarma@cff.org.br
Diretoria
Walter da Silva Jorge João, Presidente do Conselho Federal de Farmácia
Lenira da Silva Costa, Vice-Presidente do Conselho Federal de Farmácia
João Samuel de Morais Meira, Tesoureiro do Conselho Federal de Farmácia
Luiz Gustavo de Freitas Pires, Secretário-Geral do Conselho Federal de Farmácia